This study aims to identify genetic causes of adverse events after cardiac surgery, such as atrial fibrillation, myocardial infarction, renal dysfunction and heart failure.
Patients undergoing heart surgery at Brigham and Women's Hospital and Texas Heart Institute are eligible to participate.
Undergoing heart surgery
Willing to provide consent
Enrolled in a concurrent drug or device trial that precludes concurrent enrollment
Adult patients undergoing heart surgery
Cohort
Prospective
Not listed
Mortality (i.e. number of participants who are deceased during postoperative day 0 up to year 5)
Data will be collected from electronic medical records; data points to be collected for this measurement include serum creatinine.
Acute Kidney Injury using KDIGO criteria: albumin/creatinine ratio (>/= 300 mg/g) and eGRF (< 60 mL/min/1.73^2)
Data will be collected from electronic medical records; data points to be collected for this measurement include serum creatinine.
Presence of Arrhythmia (i.e. number of patients who develop an arrhythmia after their cardiac surgery)
Data will be collected from electronic medical records; data points to be collected for this measurement include post-procedural EKG reports and progress notes.
Myocardial Infarction (i.e. number of participants who develop a MI during postoperative day 0 to year 5)
Data will be collected from electronic medical records; data points to be collected for this measurement include post-procedural EKG reports, cardiac enzyme values, progress notes, and cardiac catheterization reports.
Heart failure per NYHA class II, III, IV
This will be measured in accordance to New York Heart Association Guidelines.
Click on the lead sponsor to view all of their trials.
Brigham and Women's Hospital
Lead sponsor
Johns Hopkins University
Sponsor institution
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Texas Heart Institute
Collaborator
University of Texas Southwestern Medical Center
Collaborator
Johns Hopkins University
Collaborator
